Asthma prevalence is increased in patients with high metabolism scores for visceral fat: study reports from the US

Abstract

ObjectiveData from NHANES 2001-2018 were used to examine the relationship between metabolism score for visceral fat (METS-VF) and asthma prevalence.MethodsWe assessed the association between METS-VF and asthma disease using multiple logistic regression analysis from the National Health and Nutrition Examination Survey (NHANES), 2001-2018, followed by subgroup analysis for sensitive populations. To determine whether METS-VF and asthma disease had a non-linear relationship, smooth curve fitting was used, and threshold effect analysis was used to verify the relationship.ResultsAmong the 36,876 participants, 4,919 self-reported having asthma. When all confounders were controlled for, a positive association was found between METS-VF and asthma prevalence (OR = 1.27, 95% CI: 1.22,1.32), and this positive association was stronger with elevated METS-VF (P for trend = 0.01). According to the smooth curve fitting analysis, METS-VF and asthma prevalence do not have a linear relationship. The double-segmented threshold effect analysis suggested a negative correlation but no statistically significant difference between METS-VF less than 5.24 and asthma prevalence (OR = 0.60, 95% CI: 0.33, 0.91). Besides, other METS-VF showed positive associations with asthma prevalence before and after the effective inflection point. According to subgroup analysis, METS-VF is associated with asthma prevalence among participants aged 40 – 59, male, Mexican American, with hypertension and diabetes, and without asthma history.ConclusionA positive correlation between METS-VF and asthma was observed and this positive correlation was non-linear, and participants with METS-VF above 5.24 should be cautious about the high risk of asthma. The relationship should be given more attention to participants who are aged 40-59 years old, male, Mexican American, have hypertension, diabetes, and who do not have a family history of asthma.

Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma

“…In agreement with the two aforementioned studies, the Nord-Trøndelag Health Study (HUNT) examining prospectively 23191 adults aged 19-55 years, without asthma at baseline, showed that metabolic syndrome was related to increased risk of incident asthma, indicating that physicians may take metabolic syndrome into account as a predictor of future risk of asthma [76]. The same was the result from another study that used multiple logistic regression analyses from the National Health and Nutrition Examination Survey (NHANES), 2001-2018, and found that an increase in the metabolism score for visceral fat (METS-VF) index was related to an increase in the incidence of asthma [77]. Recently, a cross-sectional analysis of 41,480 adults from the Korean National Health and Nutrition Examination Survey during the period 2007-2016, revealed that when both obesity and metabolic syndrome are present, the risk of developing asthma is highest [78].…”

Investigating a novel surrogate indicator of adipose accumulation in relation to erectile dysfunction

“…Additionally, in comparison to other evaluation indicators of obesity, METS-VF demonstrates reliability and applicability as a predictor of hypertension and diabetes within the Chinese population [ 44 , 45 ]. A 36,876-person study found a favorable correlation between METS-VF and asthma [ 21 ]. For non-obese women, the METS-VF is helpful in directing the prevention and management of hyperuricemia [ 46 ].…”

“…The formulas pertaining to these measures are presented in the following manner. Gender was presumed to be 1 because there were no female participants in this study [ 19 – 21 ].…”

Association between metabolic score of visceral fat and carotid atherosclerosis in Chinese health screening population: a cross-sectional study

“…METS-VF is closely associated with metabolic diseases, and is a reliable predictor for the development of type 2 diabetes (AUC: 0.690, 95% CI: 0.682–0.698), metabolic syndrome (AUC: 0.952, 95% CI: 0.951–0.953), non-alcoholic fatty liver disease (NAFLD) (AUC: 0.812, 95% CI: 0.802–0.823), and chronic kidney disease (AUC: 0.634, 95% CI: 0.589–0.680) [ 10 – 13 ]. Moreover, METS-VF exhibits a robust association with several diseases, including kidney stones, asthma, hypertension, and hyperuricaemia [ 14 – 17 ].…”